Skip to main content
. Author manuscript; available in PMC: 2019 Jun 26.
Published in final edited form as: Biomaterials. 2019 Mar 14;205:94–105. doi: 10.1016/j.biomaterials.2019.03.011

Figure 3. Intratumoral (i.t.) delivery is the optimal route for cGAMP MPs.

Figure 3.

Mice were inoculated with B16F10 cells on day 0. (A) On day 10, mice were injected by four routes of administration with 1 mg of Texas-red labeled cGAMP Ace-DEX MPs. Twenty-four hours later, mice were sacrificed and brain, liver, kidneys, spleen, inguinal lymph nodes, lung, and tumors were removed. Average radiance was detected by the IVIS Kinetic at an excitation wavelength of 570nm. (B) On day 10, mice were treated with 10 μg of encapsulated cGAMP. Three hours later, mice were sacrificed and tumor was removed. And homogenized. Supernatants were taken and measured for IFN-β or IL-6 ELISA. (C) On day 6, 9, and 12, mice were injected i.p., i.m., i.v., or i.t. with 10 μg of encapsulated cGAMP. Tumor were monitored every 3 days. (A. n=7–8 mice over 2 experiments, B. n=8 mice over 2 experiments, C. n=10–12 mice over 3 experiments ± SEM). A, B. One-way ANOVA, C. Two-way ANOVA. **p < 0.01, ***p < 0.001, ****p < 0.0001